Effects of combined sildenafil-nitric oxide donor on defibrillation efficacy

Journal of the Medical Association of Thailand

Volumn 90, Issue 10, 2007, Pages 2143-2149

  Shinlapawittayatorn, Krekwit ^a   Chattipakorn, Siriporn ^a   Sungnoon, Rattapong ^a   Chattipakorn, Nipon ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Defibrillation; Fibrillation; Nitroglycerin; Sildenafil citrate

Indexed keywords

GLYCERYL TRINITRATE; NITRIC OXIDE DONOR; SILDENAFIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROL GROUP; CONTROLLED STUDY; DEFIBRILLATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; ENERGY; EXPERIMENTAL PIG; HEART RATE; HEART VENTRICLE FIBRILLATION; NONHUMAN; RANDOMIZATION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ELECTRIC COUNTERSHOCK; HEART VENTRICLES; HEMODYNAMICS; MYOCARDIUM; NITRIC OXIDE; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; SWINE; VENTRICULAR FIBRILLATION;

EID: 35848958826     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
2. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-404.
3. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998; 62: L-18.
4. Park K, Moreland RB, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998; 249: 612-7.
5. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C-44C.
6. Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55: 55-9.
7. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78: 1207-13.
8. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-9.
9. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-9.
10. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576-82, A7.
11. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
12. Chiang CE, Luk HN, Wang TM, Ding PY. Effects of sildenafil on cardiac repolarization. Cardiovasc Res 2002; 55: 290-9.
13. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102: 275-7.
14. Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M, Hashimoto K. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 2001; 38: 940-6.
15. Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003; 14: 287-94.
16. Nagy O, Hajnal A, Parratt JR, Vegh A. Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 2004; 141: 549-51.
17. Vardi Y, Bulus M, Reisner S, Nassar S, Aboud L, Sprecher E, et al. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol 2003; 43: 544-51.
18. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331-4.
19. Swissa M, Ohara T, Lee MH, Kaul S, Shah PK, Hayashi H, et al. Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. Am J Physiol Heart Circ Physiol 2002; 282: H1787-92.
20. Shinlapawittayatorn K, Sungnoon R, Chattipakorn S, Chattipakorn N. Effects of sildenafil citrate on defibrillation efficacy. J Cardiovasc Electrophysiol 2006; 17: 292-5.
21. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273-82.
22. Chattipakorn N, Banville I, Gray RA, Ideker RE. Mechanism of ventricular defibrillation for near-defibrillation threshold shocks: a whole-heart optical mapping study in swine. Circulation 2001; 104: 1313-9.
23. Boddicker KA, Zhang Y, Zimmerman MB, Davies LR, Kerber RE. Hypothermia improves defibrilla tion success and resuscitation outcomes from ventricular fibrillation. Circulation 2005; 111: 3195-201.
24. Chattipakorn N, KenKnight BH, Rogers JM, Walker RG, Walcott GP, Rollins DL, et al. Locally propagated activation immediately after internal defibrillation. Circulation 1998; 97: 1401-10.
25. Rhee BJ, Zhang Y, Boddicker KA, Davies LR, Kerber RE. Effect of hypothermia on transthoracic defibrillation in a swine model. Resuscitation 2005; 65: 79-85.
26. Tang W, Snyder D, Wang J, Huang L, Chang YT, Sun S, et al. One-shock versus three-shock defibrillation protocol significantly improves outcome in a porcine model of prolonged ventricular fibrillation cardiac arrest. Circulation 2006; 113: 2683-9.
27. Chattipakorn N, Fotuhi PC, Ideker RE. Prediction of defibrillation outcome by epicardial activation patterns following shocks near the defibrillation threshold. J Cardiovasc Electrophysiol 2000; 11: 1014-21.
28. Alpaslan M, Onrat E, Samli M, Dincel C. Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. Ann Noninvasive Electrocardiol 2003; 8: 14-7.
29. Kaya D, Guler C, Esen AM, Barutcu I, Dincel C. Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. Ann Noninvasive Electrocardiol 2004; 9: 228-33.
30. Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. Am Heart J 1999; 137: 388-409.
31. Davis DR, Beatch GN, Dickenson DR, Tang AS. Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation t hreshold. Can J Cardiol 1999; 15: 193-200.
32. Umans JG, Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physiol 1995; 57: 771-90.
33. Musialek P, Lei M, Brown HF, Paterson DJ, Casadei B. Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ Res 1997; 81: 60-8.
34. Yoo KY, Kim HS, Moon JD, Lee J. Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. Anesth Analg 2002; 94: 1505-9.